abstract |
SUMMARY OF THE INVENTION The present description relates to antibody-drug conjugates directed against the cancer antigen MUC1. In particular, an antibody with improved antigen binding is obtained by suppressing a glycosylation site on CDR-H2 of a known anti-MUC1 antibody. Conjugates consist of exatecan derivatives coupled to anti-MUC1 antibodies. |